| Moderators and Speakers | |
| Foreword | |
| I | Blood Supply Systems and Organisation | |
| Blood Transfusion: Quo Vadis? Customer Orientation as the Leading Principal for Blood Banks in the Future | 3 |
| Community Involvement: The Development, the Past - the Present and the Future of Blood Donations as a Form of Community Involvement | 21 |
| Structure and Commitments - Blood Supply Systems and Organization | 31 |
| Applying Decision Analysis to Transfusion Medicine in the Real World to Improve Transfusion Safety | 37 |
| Cost-Effectiveness of HIV NAT Screening for Dutch Donors | 45 |
| Legal and Regulatory Aspects of Blood Transfusion | 53 |
| II | Technical and Pharmaceutical Developments | |
| Freezing and Vitrification of Red Cells, Recollections and Predictions | 69 |
| Plasma Fractionation | 87 |
| Viral Marker Screening: Is More Testing Safer? | 103 |
| Inactivation of Viruses, Bacteria, Protozoa, and Leukocytes in Labile Blood Components by Using Nucleic Acid Targeted Methods | 113 |
| Alternatives to Human Blood Resources | 125 |
| III | Quality Principles and Risk Management | |
| Quality Systems and Management: 2000 Where Have We Been and Where Are We Going? | 147 |
| Traceability and Coding Principles | 161 |
| Quality Principles and Risk Management: Automation and Documentation | 173 |
| Haemovigilance | 189 |
| Human Resources: Teaching and Training in Transfusion Medicine | 201 |
| IV | Transfusion Medicine at the Bedside | |
| The Epidemiology of Blood Component Transfusion in South Eastern Scotland, 1990 to 1997 | 219 |
| Contributions of Meta-Analysis to Transfusion Medicine | 229 |
| Immunomodulation: Facts and Interpretations | 251 |
| Development and implementation of New Cellular Therapies | 263 |
| Transfusion Medicine and the Development of Gene Therapy | 273 |
| Making Policy in the 2000s | 281 |
| Index | 295 |
Format: Hardcover, 302 pages
